Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[
FDG-PET/CT
Non-small cell lung cancer
Radiation treatment planning
Small cell lung cancer
Treatment response assessment
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
16
11
2021
accepted:
31
12
2021
pubmed:
24
1
2022
medline:
8
4
2022
entrez:
23
1
2022
Statut:
ppublish
Résumé
In "Joint EANM/SNMMI/ESTRO Practice Recommendations for the Use of 2-[18F]FDG-PET/CT External Beam Radiation Treatment Planning in Lung Cancer V1.0" clinical indications for PET-CT in (non-)small cell lung cancer are highlighted and selective nodal irradiation is discussed. Additionally, concepts about target definition, target delineation and treatment evaluation are reviewed.
Identifiants
pubmed: 35066001
pii: S0167-8140(22)00002-0
doi: 10.1016/j.radonc.2021.12.048
pmc: PMC9277551
mid: NIHMS1818372
pii:
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-39Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, outside the submitted work. - Rodney J. Hicks is on the Scientific Advisory Board of Telix Pharmaceuticals with any honoraria donated to his institution, he is a stock holder in this company, he is also an honorary Trustee of the International Cancer Imaging Society and honorary Board Member of Neuroendocrine Cancer Australia. - All the remaining authors declare no conflict of interest.
Références
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
Med Phys. 2006 Oct;33(10):3874-900
pubmed: 17089851
AJR Am J Roentgenol. 2019 Nov;213(5):1136-1144
pubmed: 31361525
Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1915-1927
pubmed: 28681192
Radiother Oncol. 2017 Apr;123(1):71-77
pubmed: 28284494
Med Phys. 2017 Jun;44(6):e1-e42
pubmed: 28120467
Radiother Oncol. 2017 Jul;124(1):11-17
pubmed: 28687397
Lung Cancer. 2020 Dec;150:221-239
pubmed: 33227525
Radiother Oncol. 2015 Jul;116(1):27-34
pubmed: 25869338
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1453-60
pubmed: 26830299
Radiother Oncol. 2017 Jul;124(1):1-10
pubmed: 28666551
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21
pubmed: 28881918
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36
pubmed: 19782478
Radiother Oncol. 2020 Nov;152:89-95
pubmed: 32673777
Eur Radiol. 2017 Feb;27(2):681-688
pubmed: 27180186
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
Radiother Oncol. 2012 Mar;102(3):335-42
pubmed: 22305958
J Nucl Med. 2006 May;47(5):885-95
pubmed: 16644760
Radiother Oncol. 2018 Apr;127(1):1-5
pubmed: 29605476
J Thorac Oncol. 2014 Jun;9(6):834-42
pubmed: 24787963
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Radiat Oncol. 2016 Sep 21;11(1):124
pubmed: 27655339